AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ABUS

Beardsley Robert A sold (to issuer) $90K of ABUS

Beardsley Robert A sold (to issuer) 17,948 shares of Arbutus Biopharma Corp (ABUS) at $5.00 on 2026-10-01.

Original reporting
SEC EDGAR · Beardsley Robert A
Published Oct 7, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABUS
Bearish
medium confidence
Mentioned
$ABUS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABUSBearishLow
01

Why it matters

The transaction is modest in size and unlikely to move the stock significantly, but it provides transparency for investors monitoring insider activity.

02

Market read

A routine insider sale with limited market impact; primarily of interest to compliance and monitoring teams.

03

What to watch

No other insiders have reported sales; the transaction is part of a 10b5-1 plan, suggesting pre-planned execution.

Relevance 3/10Novelty 3/10Timing: filing date Oct 7, 2026

Background

SEC Form 4 filings disclose insider transactions. This filing reports a director's sale of ABUS shares.

Company-level read

Ticker impact

$ABUSBearishMedium confidence
Context

Director Robert Beardsley sold 17,948 shares of Arbutus Biopharma for $89,740 on Oct 1, 2026, reducing his holdings to 14,328 shares.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

The sale is small ($90K) and does not represent a material change in ownership, but director disposals can be viewed as a weak negative signal.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale may be routine portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • Company
    Arbutus Biopharma Corp

    Biopharma company listed on NASDAQ under ticker ABUS.

  • Individual
    Robert A. Beardsley

    Director of Arbutus Biopharma who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABUS insider trading history →

Related articles

$ABUSMedAI 8/10

Arbutus Biopharma Updates Corporate Presentation, Reports $104.6M in Cash

Arbutus Biopharma updated its corporate presentation, reporting $104.6M in cash as of October 31, 2026. The company highlighted its hepatitis B pipeline, including 46% of Phase 2a patients achieving functional cure or discontinuing therapy, and plans for a potential Phase 2b imdusiran trial. AB-101 Phase 1 findings showed full PD-L1 receptor occupancy in 11 of 13 healthy subjects at 40 mg.

tradingview.com
$ABUSHigh

Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Geneva

SEC EDGAR 8-K
$ABUSMed

Arbutus Biopharma Corporation (ABUS) Reports $59.1M Q3 Net Income

Arbutus Biopharma reported Q3 2026 net income of $59.1M, or $0.30 per share, compared to a $7.7M net loss in Q3 2025. The company's cash and marketable securities increased to $337.5M by September 30, 2026, up from $91.5M at the end of 2025. The results reflect a shift from patent-settlement-related cash inflows and ongoing clinical development and patent litigation.

tradingview.com
$ABUSHighAI 8/10

Arbutus Biopharma Clears FDA Clinical Hold on AB-101 IND

Arbutus Biopharma (ABUS) can now advance U.S. clinical trials for AB-101 after the FDA lifted its clinical hold. The oral PD-L1 inhibitor completed a Phase 1a/1b trial, showing good tolerability and some efficacy in cHBV patients. The company is evaluating next steps for development.

tradingview.com
$ABUSHighAI 8/10

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa

SEC EDGAR 8-K